News and Press Releases 2008

November 24, 2008
Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients with Gout
October 6, 2008
Takeda’s Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
September 23, 2008
Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS® (pioglitazone HCl) for the Treatment of Type 2 Diabetes
August 13, 2008
More than 300 Takeda Employees Refurbish Waukegan's Thomas Jefferson Middle School
July 1, 2008
Takeda Pharmaceuticals and TAP Pharmaceutical Products Inc. Merge
June 7, 2008
Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
May 27, 2008
AMITIZA® (lubiprostone) 8 mcg Now Available to Treat Irritable Bowel Syndrome with Constipation in Adult Women
May 18, 2008
New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
May 17, 2008
Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation
May 12, 2008
Affymax and Takeda Announce Long-Term Hematide Safety and Effectiveness Data from Phase 2 Clinical Trials in Chronic Kidney Disease Patients with Anemia
May 1, 2008
Abbott, Takeda Conclude TAP Joint Venture
April 29, 2008
Sucampo Pharmaceuticals Obtains FDA Approval for AMITIZA® for the Treatment of Irritable Bowel Syndrome with Constipation in Adult Women
March 31, 2008
New Data Showed ACTOS® (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients with Type 2 Diabetes
March 19, 2008
Takeda Announces New U.S. Leadership
March 19, 2008
Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
January 4, 2008
Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.

Page Top